Mainz Biomed Prices $3M Follow-On Offering Including Warrants

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in early cancer detection, announced a follow-on offering of 2,222,222 units priced at $1.35 each to raise approximately $3 million in gross proceeds. Each unit consists of one ordinary share (or a pre-funded warrant) and one Series A warrant, which is immediately exercisable at $1.35 per share and expires five years from issuance. Maxim Group LLC is the sole placement agent for this offering, which closed on August 5, 2025, subject to customary conditions. The securities are offered under a registration statement declared effective by the SEC on August 4, 2025, aiming to address Mainz Biomed's short-term liquidity needs while continuing to develop diagnostic products. Despite this capital raise, the company faces financial performance challenges, including negative profitability and high leverage, with bearish stock momentum noted by analysts. The offering reflects Mainz Biomed's strategic effort to secure funding amid market conditions potentially dilutive to shareholders.